| Overview |
| bs-11248R-Cy5.5 |
| GRAF1 Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Dog, Cow, Sheep, Pig, Chicken, Rabbit |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GRAF1 |
| 1-100/814 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Cell membrane |
| arhgap 26; ARHGAP26; FLJ42530; GRAF; GRAF1; GTPase regulator associated with focal adhesion kinase; GTPase regulator associated with focal adhesion kinase pp125FAK; KIAA0621; oligophrenin 1 like protein; Oligophrenin-1-like protein; oligophrenin1like protein; OPHN1L; OPHN1L1; RHG26_HUMAN; Rho GTPase activating protein 26; Rho GTPase activating protein26; Rho GTPase-activating protein 26; Rho-type GTPase-activating protein 26. |
| Cellular signaling by G-proteins is down-regulated by GTPase-activating proteins (GAPs), which increase the rate of GTP hydroylsis. The GTPase regulator associated with focal adhesion kinase (GRAF) has GAP activity toward Rho A and Cdc42, but not Rac1. GRAF is ubiquitously expressed with high levels in heart and brain. Expression of GRAF causes clearing of stress fibers and formation of long actin based filopodial-like extensions. Fusion of MLL with GRAF, MLL/GRAF, is included in a rare genetic subgroup of acute myeloid leukemia (AML) cases. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz